RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
Key claim: A clinical trial will evaluate efficacy, safety, PK, and PD of RVU120 alone or combined with ruxolitinib in adults with intermediate- or high-risk primary or secondary myelofibrosis.
Abstract
The objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patients with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 will be given as a single agent or in combination with ruxolitinib.
Why this matters
RVU120 is an investigational agent entering formal clinical evaluation in intermediate/high-risk myelofibrosis, both as monotherapy and layered onto the ruxolitinib backbone — mirroring the dominant MF development pattern of pairing novel mechanisms with JAK inhibition. As a protocol-level announcement without efficacy readouts, it expands the pipeline of ruxolitinib add-on candidates but does not yet inform clinical decision-making. Its eventual data will help clarify whether RVU120 addresses ruxolitinib’s known gaps (limited disease modification, cytopenias, refractory disease).